Cyclic AMP comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
== Environmental record == Since 2000, the company has implemented more than 4,000 greenhouse gas reduction projects. Pfizer has inherited Wyeth's liabilities in the American Cyanamid site in Bridgewater Township, New Jersey, a highly toxic EPA Superfund site. Pfizer has since attempted to remediate this land in order to clean and develop it for future profits and potential public uses. The Sierra Club and the Edison Wetlands Association have opposed the cleanup plan, arguing that the area is subject to flooding, which could cause pollutants to leach. The EPA considers the plan the most reasonable from considerations of safety and cost-effectiveness, arguing that an alternative plan involving trucking contaminated soil off site could expose cleanup workers. The EPA's position is backed by the environmental watchdog group CRISIS. In June 2002, a chemical explosion at the Groton plant injured seven people and caused the evacuation of more than 100 homes in the surrounding area.
=== Malaysia === According to the Malaysian Food Act 1983 and Regulations (as of 5 January 2010), ractopamine is allowed in pig muscle and fat (MRL of 10 ppb), pig liver (MRL of 40 ppb), and pig kidney (MRL of 90 ppb). Ractopamine is allowed as its half-life is lower, leading to reduced residues in the food, and the dose required to affect humans is much higher than other beta agonists. On 30 December 2008, the Malaysian Veterinary Services Department quarantined 10 of the 656 pig farms in Malaysia, as the livestock were found to contain the banned chemical.
=== 19 May === The Ukrainian military said it had repelled another Russian air attack in the morning, destroying 19 drones and three Kalibr missiles out of a total of 28 launched. An elderly woman was seriously injured during airstrikes on Kryvyi Rih. The Pentagon announced that it had made an accounting error in relation to the aid supplied to Ukraine. The error was made when the Pentagon overestimated to Congress, by at least $3 billion, the cost of weapons sent to Ukraine. This error meant that these funds were effectively a surplus that could be spent on more weapons for Ukraine. President Biden said he would support a joint effort with allies to train Ukrainian pilots on fourth generation aircraft, including F-16s fighter jets. Shortly afterwards, Denmark said it would provide direct help in training. No date was announced for such training to commence. Once it does it could take six to nine months to properly train Ukrainian pilots and crews to use the F-16. A US official told CNN that the United States was prepared to help train Ukrainian pilots on the F-16. The training would take place in Europe in the "coming weeks", along with European allies, while a decision on the number of aircraft would be made at a later date. During the 49th G7 summit in Hiroshima, Japan, UK Prime Minister Rishi Sunak announced that the government was introducing new sanctions against Russian exports, particularly on diamonds, nickel, copper and aluminum.
Sources: en.wikipedia.org
== Career == Following his Doctoral degree, Greenspan joined Yale University School of Medicine as a Postdoctoral fellow in the Department of Genetics. In 1984, he was appointed as an Associate Research Scientist in the Department of Genetics and was supported by a fellowship from the Arthritis Foundation. His postdoctoral studies at Yale included analysis of RNA splicing and identification of new human HLA genes. He subsequently joined the University of Wisconsin-Madison School of Medicine in 1986 as assistant professor in the Department of Pathology and Laboratory Medicine. Greenspan was promoted to Associate Professor in 1992, and became a Professor in 1997. From 2010 – 2014 Greenspan served as founding/interim chair of the Department of Cell and Regenerative Biology at the University of Wisconsin School of Medicine and Public Health. Prior to that, he was Vice Chair for Research in the Department of Pathology and Laboratory Medicine from 2003 to 2006.
The predictions of the effects of a major countervalue nuclear exchange include millions of city dweller deaths within a short period of time. Some 1980s predictions had gone further and argued that a full-scale nuclear war could eventually bring about human extinction. Such predictions, sometimes but not always based on total war with nuclear arsenals at Cold War highs, received contemporary criticism. On the other hand, some 1980s governmental predictions, such as FEMA's CRP-2B and NATO's Carte Blanche, have received criticism from groups such as the Federation of American Scientists for being overly optimistic. CRP-2B, for instance, predicted that 80% of Americans would survive a nuclear exchange with the Soviet Union, a figure that neglected nuclear war's impacts on healthcare infrastructure, the food supply, and the ecosystem and assumed that all major cities could be successfully evacuated within 3–5 days. A number of Cold War publications advocated preparations that could purportedly enable a large proportion of civilians to survive even a total nuclear war. Among these is Nuclear War Survival Skills. To avoid injury and death from a nuclear weapon's heat flash and blast effects, the two most common causes of injury from nuclear weapons, schoolchildren were taught to duck and cover by the early Cold War film of the same name. Such advice is once again being given in case of nuclear terrorist attacks.
=== Legal status === In September 2018, galcanezumab was approved in the United States for the preventive treatment of migraine in adults. The FDA granted the approval of Emgality to Eli Lilly. In November 2018, galcanezumab was approved for use in the European Union for the prophylaxis of migraine in adults who have at least four migraine days per month. In June 2019, galcanezumab was approved in the United States for the treatment of episodic cluster headache in adults. The application for galcanezumab was granted priority review and breakthrough therapy designations. In January 2021, AffaMed Therapeutics signed an agreement with Lilly to distribute galcenazumab in China. In December 2023, Organon signed an exclusive agreement with Lilly to distribute and commercialize galcanezumab in Europe. In August 2024, the agreement between Organon and Lilly was expanded to include a further 11 worldwide markets.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.